Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited, a biotech company specializing in cell therapy for cancer treatment, has announced that 413,379 of its Ordinary Shares will be released from voluntary escrow on June 30, 2024. These shares were initially issued in exchange for investor relations services. The company is advancing its cell therapy platform, including its lead product ALA-101, targeting blood cancers and solid tumors through CAR19-iNKT cells and its CLDN18.2-targeting technology.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
